Fulgent Genetics, Inc. Q1 2026 Financial Report – Detailed Analysis for Investors
Fulgent Genetics, Inc. Q1 2026 Financial Report – Detailed Analysis for Investors
Key Highlights and Investor Relevant Points
- Quarterly Report Context: This is the Q1 2026 report, covering the period ended March 31, 2026.
- Common Stock Information: As of April 27, 2026, there were 28,400,623 outstanding shares of common stock, with a par value of \$0.0001 per share. The company is listed on the Nasdaq Global Market under the trading symbol “FLGT.”
- Company Status: Fulgent Genetics is NOT a shell company, is NOT an emerging growth company, and is classified as a smaller reporting company. It has filed all required reports and submitted all required interactive data files.
- Change in Company Name: The company was formerly known as Fulgent Diagnostics, Inc., with the name change taking effect on May 17, 2016.
- Business Address: 4399 Santa Anita Ave, El Monte, CA 91731.
Condensed Consolidated Balance Sheet Highlights
| Balance Sheet Item |
March 31, 2026 (USD, \$000s) |
December 31, 2025 (USD, \$000s) |
| Cash and Cash Equivalents |
50,193 |
N/A |
| Marketable Securities (Current) |
252,903 |
285,884 |
| Other Current Assets |
24,298 |
N/A |
| Total Current Assets |
479,042 |
550,490 |
| Marketable Securities (Long-Term) |
328,287 |
369,269 |
| Other Long-Term Assets |
24,976 |
N/A |
| Total Assets |
1,156,369 |
1,213,525 |
| Notes Payable (Current) |
482 |
476 |
| Other Current Liabilities |
9,372 |
7,624 |
| Stockholders’ Equity |
Common stock: \$0.0001 par, 50,000,000 authorized, 34,870,000 issued, 28,851,000 outstanding
Additional Paid-in Capital: 540,141
Accumulated Other Comprehensive Income: Not specified |
Common stock: \$0.0001 par, 50,000,000 authorized, 34,501,000 issued, 31,081,000 outstanding
Additional Paid-in Capital: 574,520
Accumulated Other Comprehensive Income: Not specified |
Potential Price-Sensitive Information for Shareholders
- Decrease in Total Assets: Total assets declined from \$1,213.5 million at December 31, 2025 to \$1,156.4 million at March 31, 2026. This signals a reduction in the company’s asset base, which may be due to operating losses, investments, or asset sales.
- Decrease in Marketable Securities: Both current and long-term marketable securities have decreased since the last reporting period, suggesting possible investment liquidation or portfolio adjustments.
- Increase in Notes Payable/Current Liabilities: Notes payable and other current liabilities have increased slightly, which may indicate increased short-term borrowing or higher accruals.
- Decrease in Additional Paid-In Capital: Paid-in capital has dropped from \$574.5 million to \$540.1 million, which could reflect share repurchases, employee stock plan activity, or other equity transactions.
- Decrease in Common Stock Outstanding: Shares outstanding decreased from 31,081,000 to 28,851,000, potentially indicating share buybacks, cancellations, or other capital actions.
- Commitments and Contingencies: The company references commitments and contingencies (Note 8), which may include legal, operational, or financial obligations – details should be reviewed in Note 8 for potential risks.
- No Preferred Stock Issued: Although there are 1,000,000 shares authorized, no preferred stock is issued or outstanding as of the reporting dates.
- Segment and Geographic Information: The company operates in laboratory services and therapeutic development, with assets in both the US and other countries.
Important Considerations for Investors
- All reporting obligations and interactive data requirements have been met, reflecting regulatory compliance and transparency.
- The company is listed on Nasdaq, and its trading symbol is “FLGT.”
- Fulgent Genetics is not an emerging growth company or shell company, which may affect how investors view its risk and growth profile.
- Changes in asset values, liabilities, and equity could have implications for future earnings, dividends, or capital structure. Investors should monitor these trends closely.
- Details on commitments and contingencies (especially Note 8) may represent risks, obligations, or opportunities that could impact future performance and share price.
Summary Table of Potential Share Price Movers
| Potential News/Trigger |
Possible Impact |
| Decrease in total assets and marketable securities |
Could signal cash burn, asset sales, or operational losses – negative for share value if sustained |
| Increase in liabilities (notes payable, current liabilities) |
May increase financial risk or signal near-term cash needs |
| Decrease in outstanding shares |
Possible share repurchases/cancellations, which can be positive if buybacks, negative if cancellations due to losses |
| Reference to Commitments and Contingencies |
Could represent hidden risks (e.g., lawsuits, regulatory issues, or contracts); investors should review Note 8 |
| Changes in segment reporting |
May signal business diversification or restructuring |
Conclusion
Fulgent Genetics, Inc.’s Q1 2026 financial report reveals several changes in asset values, liabilities, and equity which investors should monitor closely. The reduction in assets and marketable securities, along with changes in equity and liabilities, may be indicative of operational or financial adjustments that could impact future share value. Additionally, shareholders should pay attention to any commitments and contingencies disclosed in Note 8, as these may represent price-sensitive risks.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should review the full financial statements, including all notes and disclosures, and consult with their financial advisors before making investment decisions. The information summarized herein is based on the company’s SEC filings and may be subject to change or interpretation. No liability is accepted for any actions taken based on this information.
View Fulgent Genetics, Inc. Historical chart here
